Skip navigation

Dr Sterghios Moschos

Associate Professor

Department: Applied Sciences

Trained as a Molecular Biologist at the University of Portsmouth, Sterghios did his PhD in Pharmaceutics on nasal vaccines with Prof. Oya H. Alpar at the Centre for Drug Delivery Research, School of Pharmacy, which is now part of UCL. After a 3-year post-doc on genetic adjuvants and siRNA formulation science, he joined Prof. Mark A. Lindsay, Maria Belvisi and Peter J. Barnes at the National Heart and Lung Institute, Imperial College, to explore cell penetrating peptide-mediated siRNA delivery to the lungs. Here, he expanded this work to biodefence (with dstl), and describing the microRNA regulatory networks in airway inflammatory disease.

He was then headhunted in 2008 by Pfizer Global Research and Development at Sandwich, Kent, to lead oligonucleotide therapeutics research for respiratory indications. Working parallel to Art Krieg’s RNAi-focused Pfizer Research Technology Centre, and closely with colleagues within the Pfizer Coley Pharmaceutical Group, Pfizer Antivirals and Tacere (later acquired by Benitec), Sterghios was instrumental in ensuring the safety of DNA-directed RNAi gene therapy for hepatitis C virus, pioneering inhaled administration of oligonucleotide drugs for liver and kidney diseases, and developing novel methods for reducing animal use in pharmacology research by up to 66%. His work was recognised as breakthrough by the American Society of Gene and Cell Therapy, defining pharmaceutical sector strategy in terms of antisense and RNAi therapies for the lung.

Joining the University of Westminster in 2011 as a Reader in Industrial Biotechnology and Biochemistry, Sterghios established Westminster Genomic Services around the then emerging Ion Torrent next generation sequencing platform to receive the first Certified Service Provider status in the UK, offering GLP-grade internal and external research services. Devising the RACE-SEQ method now established across the RNAi industry, and crucial in the accelerated initiation of first-in-human clinical trials for DNA-directed RNAi, he was the first to digitally quantify the imprecision of human Argonaute 2 activity. Working closely with Prof. Izzet Kale (Dept. Electronic Engineering, University of Westminster), Sterghios also developed PulmoScreen, a novel, patent-protected exhaled breath condensate collection device platform. Responding to the emerging need of the West African Ebolavirus outbreak, Sterghios established and lead the EbolaCheck consortium to conceive, design, deliver and validate with 12 months the first nucleic acid amplification test (NAAT) screening platform. The technology is suited for laboratory-free use at the point of need in resource-limited settings, is now available commercially and for future use in screening symptomatic patients for Ebolavirus disease, and under further development for pre-symptomatic differential diagnosis of multiple haemorrhagic fevers.

LinkedIn

Featured Video

Campus Address

Room 2.24 D Block
Ellison Building
City Campus

Qualifications

  • PhD October 01 2004
  • Molecular Biology BSc (Hons) July 10 1999
  • Fellow (FHEA) Higher Education Academy (HEA) 2017
  • Fellow Institute of Biomedical Science (IBMS) 2015
  • Fellow (FRSC) Royal Society of Chemistry (RSC) 2014
  • Full Member Genetics Society 2012
  • Full Member Biochemical Society 2005
  • Full Member Society for General Microbiology (SGM) 1998

Key Publications

  • Please visit the Pure Research Information Portal for further information
  • Measuring the action of oligonucleotide therapeutics in the lung at the cell type specific level by Tissue Disruption and Cell Sorting (TDCS), Graves, H., Evans, S., Fauler, M., Frick, M., Moschos, S. 8 Jan 2019, Oligonucleotide-based Therapies, Springer
  • RACE-SEQ and population-wide polymorphism susceptibility testing for endonucleotically active, RNA-targeting therapeutics, Moschos, S., Usher, L., Theotokis, P. 10 Jan 2019, Oligonucleotide-based Therapies, Springer
  • The emerging field of venom-microbiomics for exploring venom as a microenvironment, and the corresponding Initiative for Venom Associated Microbes and Parasites (iVAMP), Ul-Hasan, S., Rodriguez-Roman, E., Reitzel, A., Adams, R., Herzig, V., Trim, S., Saviola, A., Nobile, C., Stiers, E., Moschos, S., Keiser, C., Petras, D., Moran, Y., Colston, T. 20 Sep 2019, In: Toxicon: X
  • A novel antifungal property for the Bacillus licheniformis ComX pheromone and its possible role in inter-kingdom cross-talk, Esmaeilishirazifard, E., Dariush, A., Moschos, S., Keshavarz, T. Jun 2018, In: Applied Microbiology and Biotechnology
  • Extracellular vesicles and their nucleic acids for biomarker discovery, Momen-Heravi, F., Getting, S., Moschos, S. 3 Aug 2018, In: Pharmacology and Therapeutics
  • Gene therapies are proving their worth, but with million dollar price tags, it’s not clear who should pay for them, Moschos, S. 26 Mar 2018
  • PulmoScreen: A Novel Exhaled Breath Condensate Device, Clements, C., Wilkinson, A., Shah, K., Moschos, S. 22 Nov 2018
  • PulmoScreen: Solving exhaled breath molecular diagnostics, Moschos, S. Nov 2018
  • Bedside NGS diagnostics for the oligonucleotide therapeutics market: from patient selection to drug efficacy quantification, Moschos, S. 12 Jul 2017
  • BreatheIN: Realising the Clinical Potential of Oligonucleotide Rx for Respiratory Disease, Moschos, S. 1 Feb 2017

PGR Supervision

  • Ifeanyi Enekwa Start: 01/02/2018
  • Joseph O'Sullivan Start: 15/10/2018
  • Eleni Eftychiou Start: 01/10/2017


+

Northumbria Open Days

Open Days are a great way for you to get a feel of the University, the city of Newcastle upon Tyne and the course(s) you are interested in.

Research at Northumbria
+

Research at Northumbria

Research is the life blood of a University and at Northumbria University we pride ourselves on research that makes a difference; research that has application and affects people's lives.

+

Order your prospectus

If you would like to know more about our courses, or life in general as a student at Northumbria, then we can help you.

Latest News and Features

More news
More events

Upcoming events

Assessment Centres - what to expect and how to practice
Explore your career options

Back to top